Teva reached a settlement with the Federal Trade Commission to resolve an antitrust suit that charged the drugmaker's subsidiary Cephalon with illegally blocking generic competition for narcolepsy drug Provigil.
The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate
The updated app now tracks everyday health metrics including weight, activity and glucose levels.
Multiple marketing channels offer an effective way to ensure that meaningful relationships can be developed with prospects and when done right can increase revenue by more than 10% while reducing costs by 25%, if not both
While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen outlines the potential threats and solutions
The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.
The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.
Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.
Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill
Long considered one of the staid, self-contained areas of the healthcare biz, the device/diagnostics space has enjoyed an injection of energy as the potential for integration with mobile devices has become more obvious. But are these companies set up to work alongside their traditional pharma partners, much less the entrepreneurial-minded start-ups that aim to reinvent the category? Larry Dobrow surveys the opportunities and frustrations